Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings.

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials.

OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.

This month, the Journal of the American Medical Association (JAMA) published a collaborative article between the Children’s Hospital of Philadelphia and the University of California concerning the ...

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

The White House’s decision to safeguard $400m in President’s Emergency Plan for AIDS Relief (PEPFAR) funding to support the global human immunodeficiency virus (HIV) emergency provides “hope” to ...

SELLAS AML therapy achieved an overall response rate of 33%, exceeding the 20% threshold, with some patient groups achieving 50% ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.